Biotech Values

[mcbio]

The Copaxone language in Teva’s 20-F filing is somewhat different from the bluster you hear from executives on investor presentations. The 20-F says:

www.sec.gov/Archives/edgar/data/818686/000119312512067417/d300203d20f.htm
Quote:
--------------------------------------------------------------------------------
…our patents on Copaxone have been challenged, and we may face generic competition prior to 2014, when the U.S. Orange Book patents covering Copaxone would otherwise expire.
--------------------------------------------------------------------------------

On investor CC’s, Teva’s executives say that there’s no chance in hell this can occur.

Do you view the FDA approval decision as more important for mC than the patent litigation decision since Copaxone's patents are going to expire in a few years anyways?